Paper Targets: Why Europe Will Miss Its 2030 Hepatitis Goals

There is a familiar rhythm to European Union policy-making: announce a utopian target for a round-number year, establish an extensive monitoring framework, and eventually publish a report explaining why the goal will not be met. The year 2030 was supposed to mark the end of hepatitis B and C across the continent. Instead, the European Centre for Disease Prevention and Control has quietly conceded that this deadline is slipping out of reach. The bureaucratic machine in Stockholm has issued its warning, yet the underlying structural inertia remains entirely untouched.

The statistics provided by the agency are grim, painting a picture of administrative ambition clashing with biological reality. Roughly five million Europeans are currently living with chronic hepatitis B or C, often unaware of their status until severe liver disease manifests. Annually, these infections claim around 60,000 lives. Bruno Ciancio, a senior official at the agency, recently pointed out that these diseases are entirely preventable, diagnosable, and treatable. Yet, the European health apparatus seems vastly better equipped to measure the shortfall than to actually remedy it. The disconnect between grandiose central planning and the reality of public health implementation across member states is glaring.

Take the fundamental tools of prevention: vaccines and sterile needles. The World Health Organization set a straightforward benchmark requiring 95 percent of children to be fully vaccinated against hepatitis B. Only a minority of European nations actually hit this mark, with some even reporting a regression in coverage. Harm reduction strategies face a similar fate. While providing sterile injection equipment to drug users is a proven method to halt the spread of hepatitis C, a mere seven countries currently meet the established distribution targets. The central authorities dictate best practices but lack the mandate, accountability, or practical competence to enforce them on the ground.

There are, admittedly, pockets of success. Acute hepatitis B cases have been declining since 2006. Among those under twenty-five, the share of acute infections dropped from 11 percent in 2015 to 8 percent over the past decade. Routine maternal screening across the thirty countries of the European Economic Area has successfully pushed mother-to-child transmission below 2 percent.

However, when addressing persistent transmission routes—such as sexual contact or intravenous drug use—the agency’s primary grievance is highly revealing. Rather than questioning the efficacy of the interventions themselves, the official complaint is that prevention efforts are not being systematically monitored across different populations. It is a classic bureaucratic reflex: when a policy fails to deliver results, the proposed solution is simply to demand more administrative paperwork.

Ultimately, eliminating a virus requires more than generating data points and setting arbitrary deadlines. The current trajectory suggests that the 2030 target was always more about political optics than achievable public health reality. As long as the European health architecture prioritises administrative oversight over pragmatic action, the targets will continue to shift, and the bureaucratic machine will continue to hum along, perfectly insulated from the consequences of its own ineffectiveness.

Written by Thomas Nussbaumer thomas.nussbaumer@alpineweekly.com